Last updated: February 15, 2026
Product Overview
NDC 51407-0070 corresponds to Spravato (esketamine) nasal spray, approved by the FDA in March 2019 for treatment-resistant depression (TRD) in adults. It is marketed by Johnson & Johnson and has gained significant attention due to its novel mechanism and rapid onset of antidepressant effects.
Market Size and Patient Demographics
1. Addressable Population
- Treatment-resistant depression (TRD): Estimated prevalence in the U.S. is approximately 2.8% of adults. Based on CDC data, roughly 5 million adults are affected.
- Eligibility: Clinical guidelines specify patients who have not responded to at least two antidepressant treatments in the current episode.
- Market Penetration: Historically, injectable ketamine has been used off-label; however, Spravato's FDA approval created a new treatment paradigm.
2. Current Market Penetration
- Prescriptions (2022): Approximately 125,000 - 150,000 prescriptions in the U.S. (IQVIA data).
- Market Share: Dominates the nasal spray segment, with an estimated 85% of prescriptions for nasal esketamine formulations.
3. Competitive Landscape
- Other Treatments: Oral antidepressants, psychotherapy, electroconvulsive therapy (ECT), and off-label ketamine infusion. No direct approved competitors for nasal esketamine, though compounded ketamine infusions are used off-label, influencing demand.
Pricing and Revenue
1. Current Pricing
-
National Average Wholesale Price (AWP): Approximately $885 per treatment session (per actuation).Each treatment usually involves two administrations per week for four weeks, totaling eight sessions per month.
-
Commercial Payers: Reimbursements are often negotiated at discounts ranging from 15% to 30% off AWP.
-
Patient Out-of-Pocket: Under Medicare, cost varies but can be $15-$50 per session with Part D coverage. Commercial insurances may cover up to 80% after deductible.
2. Revenue Estimates (2022)
| Estimated Prescriptions |
Units per Prescription |
Revenue per Prescription |
Annual Revenue Estimate |
| 125,000 - 150,000 |
8 sessions per prescription |
$7,080 (at $885/session) |
$885 million (low estimate) |
|
|
|
$1.33 billion (high estimate, with high reimbursement) |
Note: Revenue calculations assume brand price points and do not account rebates, discounts, or administrative costs.
Market Growth Factors
- Clinical Adoption: Increasing recognition of TRD's refractoriness and the rapid onset of esketamine versus traditional antidepressants.
- Insurance Coverage: Expanded Medicaid and commercial insurance coverage expands accessible patient pools.
- Physician Education: Training programs improve provider familiarity, expanding access points.
- Global Expansion: Approval in Canada (2019) and Europe (2020s) could result in future revenue increases.
Price Projections (Next 3-5 Years)
| Year |
Estimated Prescription Volume |
Price per Session |
Expected Revenue |
| 2023 |
150,000 |
$885 |
$1.33 billion |
| 2024 |
170,000 |
$870 (slight price decline) |
$1.48 billion |
| 2025 |
200,000 |
$855 |
$1.71 billion |
Assumption: gradual market saturation, slight pricing pressure, and increased competition from generics or biosimilars.
Generic and Biosimilar Considerations
- Patent Status: Johnson & Johnson's formulation patent expired or will expire by 2024, opening the door to biosimilar development.
- Impact on Prices: Entry of biosimilars could reduce prices by 20-50%, depending on market acceptance and regulatory approval timelines.
- Pricing Dynamics: Competitive biosimilars could force list prices down, impacting revenue margins.
Regulatory and Policy Factors
- Reimbursement Policies: Increasing Medicare and Medicaid coverage set a precedent.
- Value-Based Pricing: Payers may negotiate prices based on clinical outcomes, possibly reducing per-session revenue.
- Global Approval Pipeline: European Medicines Agency (EMA) and other regulatory bodies are evaluating esketamine for broader indications, expanding potential markets.
Risks and Challenges
- Reimbursement Delays: Payer resistance or limited formulary inclusion could hamper market penetration.
- Off-Label Competition: Off-label compounded ketamine treatments may limit demand growth.
- Pricing Pressures: Biosimilar entry and negotiations could drive prices downward.
Key Takeaways
- NDC 51407-0070 (Spravato) has a growing market driven by increasing TRD prevalence and clinical adoption.
- Current revenue estimates for 2022 hover near $1.3 billion, with a trajectory toward $1.5-$2 billion by 2025.
- Price per session is approximately $885, with potential downward pressure from biosimilar competition.
- Reimbursement environments and global approvals could further influence market size and pricing strategies.
- Market expansion hinges on clinician education, insurance coverage, and evolving treatment guidelines.
FAQs
Q1: What is the primary indication for NDC 51407-0070?
A1: Treatment-resistant depression in adults.
Q2: What are the typical treatment costs and reimbursement patterns?
A2: Approximately $885 per session, with insurer reimbursements often ranging from 70%-85%; patient out-of-pocket costs are significantly lower with insurance.
Q3: How might biosimilar entry affect prices?
A3: Biosimilar competition could reduce prices by 20-50%, potentially decreasing revenue margins.
Q4: What factors influence future market growth?
A4: Expanded clinical adoption, broader insurance coverage, increasing global approvals, and competition dynamics.
Q5: Are there any upcoming regulatory changes that could impact pricing?
A5: Yes. Biosimilar approvals and value-based reimbursement models can shift pricing, as well as policies expanding indications or coverage parameters.
Sources
[1] IQVIA, "Prescription Data 2022"
[2] FDA, "Spravato (esketamine) prescribing information," 2019
[3] CDC, "Depression Prevalence Estimates," 2021
[4] CMS, "Medicare Part D Drug Spending Data," 2022
[5] European Medicines Agency, "Assessment reports for esketamine," 2022
